Pro Medicus (ASX:PME) Other Long Term Assets: A$37.9 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:PME Pro Medicus Ltd ASX:PME
100 GF Score
Price A$190.60
GF Value A$255.75
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Pro Medicus Other Long Term Assets?

Pro Medicus ASX:PME -1.46% 100 Other Long Term Assets is A$37.9 Mil as of Jun. 2026. GuruFocus rates ASX:PME with a GF Score™ of 100/100 and a GF Value™ of A$255.75 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Pro Medicus's other long-term assets for the quarter that ended in Jun. 2026 was A$37.9 Mil.

Pro Medicus's quarterly other long-term assets increased from Jun. 2025 (A$27.7 Mil) to Dec. 2025 (A$36.1 Mil) and increased from Dec. 2025 (A$36.1 Mil) to Jun. 2026 (A$37.9 Mil).

Pro Medicus's annual other long-term assets increased from Jun. 2024 (A$21.1 Mil) to Jun. 2025 (A$27.7 Mil) and increased from Jun. 2025 (A$27.7 Mil) to Jun. 2026 (A$37.9 Mil).

Pro Medicus Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Pro Medicus's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pro Medicus Other Long Term Assets Chart

Pro Medicus Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.33 14.81 21.08 27.74 37.95

Pro Medicus Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.08 24.16 27.74 36.14 37.95
ASX:PME
100GF Score
Pro Medicus Ltd ASX:PME
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pro Medicus Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of A$37.9 Mil mean?
Pro Medicus (ASX:PME) has a Other Long Term Assets of A$37.9 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Pro Medicus and its competitors.
Is Pro Medicus' Other Long Term Assets too high?
Pro Medicus' current Other Long Term Assets is A$37.9 Mil. Overall, Pro Medicus has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pro Medicus' Other Long Term Assets compare to VEEV and BTSG?
Pro Medicus' Other Long Term Assets of A$37.9 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Healthcare Providers & Services company?
A good Other Long Term Assets depends on the Healthcare Providers & Services industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Pro Medicus and its competitors. Pro Medicus's current Other Long Term Assets is A$37.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pro Medicus stock overvalued right now?
Based on GuruFocus' analysis, Pro Medicus (ASX:PME) is currently considered Modestly Undervalued. The stock's GF Value™ is A$255.75, compared to a current price of A$190.60 — trading 25.5% below its estimated fair value. The current Other Long Term Assets is A$37.9 Mil. Pro Medicus' overall GF Score™ is 100/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Pro Medicus (ASX:PME), the current Other Long Term Assets is A$37.9 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pro Medicus (ASX:PME) Overvalued in 2026?

Based on GuruFocus' analysis, Pro Medicus stock appears to be undervalued. The current stock price of A$190.60 is trading 25.5% below its estimated GF Value™ of A$255.75. GuruFocus considers Pro Medicus to be Modestly Undervalued.

Key valuation signals for ASX:PME:

  • Other Long Term Assets: A$37.9 Mil
  • GF Value™: A$255.75 vs. price of A$190.60 (25.5% below fair value)
  • GF Score™: 100/100 with 3 warning signs

No single metric tells the full story. See the ASX:PME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pro Medicus Business Description

Address 450 Swan Street, Richmond, VIC, AUS, 3121
Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are US private academic hospitals. In fiscal 2025, Pro Medicus earned 90% of revenue in North America, 8% from Australia, and the remaining 2% in Europe.
100GF Score

Get the complete analysis for ASX:PME

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$190.60
Price
A$255.75
GF Value